COMMUNIQUÉS West-GlobeNewswire

National Healthcare Economics and Policy Expert Ruben Jose King-Shaw Jr Joins CURE Pharmaceutical’s Board of Directors

29/01/2019 - 13:25

The drug delivery leader taps former COO of U.S. Centers for Medicare & Medicaid Services to join growing Board OXNARD, Calif., Jan. 29, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug [...]

IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA

29/01/2019 - 13:05

DECIDE phase 2 clinical trial amendment successfully completed with multiple sites now open for enrollment FDA provided guidance for future registration trial design and for a potential shorter regulatory pathway for [...]

Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia

29/01/2019 - 13:00

Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine Biosciences gains development and [...]

Aravive to Host Key Opinion Leader Breakfast Symposium on AVB-S6-500 and the GAS6-AXL Pathway on February 5, 2019

29/01/2019 - 13:00

HOUSTON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) symposium focused on the GAS6-AXL pathway [...]

FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy

29/01/2019 - 13:00

Largest transaction to date for Canadian-discovered preclinical asset arises from Ontario collaborators TORONTO, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, together with its majority shareholder FACIT, [...]

LHC Group Appoints National Healthcare Veteran Teri G. Fontenot to Board of Directors

29/01/2019 - 12:30

LAFAYETTE, La., Jan. 29, 2019 (GLOBE NEWSWIRE) -- LHC Group, Inc. (NASDAQ: LHCG) announced today that it has appointed Teri G. Fontenot to the Board of Directors, effective March 1, 2019. Ms. Fontenot, who will serve as [...]

Emerald Health Therapeutics’ Licensed Endo Product Line Gains Boost with Entry into Whole Foods Market Stores Across US

29/01/2019 - 12:00

Emerald Health Therapeutics and Emerald Health Naturals on track to launch endocannabinoid-supporting products in Canada VICTORIA, British Columbia, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“ [...]

Managers’ transactions

29/01/2019 - 10:51

Company Announcement No. 3/2019 January 29, 2019 For further information please contact: Martin Riise, Senior Director, Investor Relations, Tel: +45 5339 2250 Camilla Lercke, Head of Media Relations, Tel: +45 5339 2384 [...]

Nicox : Aval de la FDA américaine pour l'Investigational New Drug du NCX 4251 pour une étude de phase 2 dans la blépharite

29/01/2019 - 07:31

Communiqué de presse Nicox : Aval de la FDA américaine pour l'Investigational New Drug du NCX 4251 pour une étude de phase 2 dans la blépharite ................................................. 29 janvier 2019 - [...]

Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis

29/01/2019 - 07:30

Press Release Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis ................................................ January 29 th , 2019 - release at 7:30 [...]

Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES

29/01/2019 - 07:01

PRESS RELEASE : REGULATED INFORMATION 29 January 2019, 07:00 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 29 January 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative [...]

INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME

29/01/2019 - 07:00

INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME Fast Track designation (FTD) is intended to expedite the development and regulatory review of IPH4102 for the [...]

INNATE PHARMA REÇOIT LE STATUT « FAST TRACK » DE LA FOOD AND DRUG ADMINISTRATION (FDA) POUR IPH4102 CHEZ LES PATIENTS PRÉSENTANT UN SYNDROME DE SÉZARY EN RECHUTE OU RÉFRACTAIRE

29/01/2019 - 07:00

INNATE PHARMA REÇOIT LE STATUT « FAST TRACK » DE LA FOOD AND DRUG ADMINISTRATION (FDA) POUR IPH4102 CHEZ LES PATIENTS PRÉSENTANT UN SYNDROME DE SÉZARY EN RECHUTE OU RÉFRACTAIRE Le statut « Fast Track » vise à accélérer [...]

Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock

29/01/2019 - 04:33

RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today [...]

Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement

28/01/2019 - 23:23

HAMILTON, Bermuda, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of 8,000,000 Class A common shares. [...]

IMV to Present at 2019 BIO CEO & Investor Conference

28/01/2019 - 22:35

DARTMOUTH, Nova Scotia, Jan. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will participate in the BIO CEO and Investor Conference [...]

Akorn Announces New Executive and Board Appointments

28/01/2019 - 22:30

LAKE FOREST, Ill., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), today announced that it has appointed a new executive team member and two new board members. Christopher C. Young joins Akorn as Executive [...]

Myriad to Announce Fiscal Second-Quarter 2019 Financial Results on February 5, 2019

28/01/2019 - 22:05

SALT LAKE CITY, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal second-quarter 2019 sales [...]

Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical Officer

28/01/2019 - 22:05

BURLINGAME, Calif., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted [...]